Management of Acute Psychosis with Antipsychotic Medication

Initial Assessment and Treatment

• Short-term use of benzodiazepines as adjuncts to antipsychotics may help stabilize the clinical situation, according to the American Academy of Child and Adolescent Psychiatry 1

Pharmacological Management Algorithm

• Implement treatment for 4-6 weeks using adequate dosages before determining efficacy, as recommended by the American Academy of Child and Adolescent Psychiatry 1
• Any immediate effects are likely due to sedation, with antipsychotic effects becoming apparent after 1-2 weeks, according to the American Academy of Child and Adolescent Psychiatry 1
• Avoid large initial doses as they don't hasten recovery but increase side effects, as noted by the American Academy of Child and Adolescent Psychiatry 1

If First Treatment Fails

• If no results after 4-6 weeks or if side effects are unmanageable, switch to a different antipsychotic, as suggested by The Lancet Psychiatry 2
• When switching antipsychotics, choose a compound with a different pharmacodynamic profile, according to The Lancet Psychiatry 2
• For patients whose first-line treatment was a D2 partial agonist, consider amisulpride, risperidone, paliperidone, or olanzapine as second-line treatment, as recommended by The Lancet Psychiatry 2

Treatment-Resistant Cases

• If positive symptoms remain significant after two adequate treatment trials (at least 4 weeks each), reassess diagnosis and contributing factors, as advised by The Lancet Psychiatry 2
• Consider clozapine for treatment-resistant cases, as it's the only antipsychotic with documented superiority for treatment-refractory schizophrenia, according to the American Academy of Child and Adolescent Psychiatry and The Lancet Psychiatry 2, 3
• Clozapine should be used only after failure to respond to at least two therapeutic trials of other antipsychotic agents (at least one being an atypical antipsychotic), as recommended by the American Academy of Child and Adolescent Psychiatry 3

Transition from Acute to Maintenance Phase

• The recuperative phase occurs after 4-12 weeks if the acute phase is controlled, according to the American Academy of Child and Adolescent Psychiatry 1
• Maintain antipsychotic medication during this period as additional improvement may occur over 6-12 months, as suggested by the American Academy of Child and Adolescent Psychiatry 1
• Consider gradual dose reduction to decrease side effects, especially if high doses were needed for acute control, as recommended by the American Academy of Child and Adolescent Psychiatry 1

Special Considerations

• Individual responses to different antipsychotics are variable, as noted by the American Academy of Child and Adolescent Psychiatry 3
• Atypical agents may be more effective for negative symptoms, according to the American Academy of Child and Adolescent Psychiatry 3
• For adolescents, depot antipsychotics should only be considered with documented chronic psychotic symptoms and poor medication compliance, as recommended by the American Academy of Child and Adolescent Psychiatry 1
• Monitor for side effects carefully, especially in youth where these medications have not been well studied, as advised by the American Academy of Child and Adolescent Psychiatry 4

Common Pitfalls to Avoid

• Avoid excessive initial dosing which leads to unnecessary side effects, as warned by the American Academy of Child and Adolescent Psychiatry 1
• Don't switch medications too early (before 4-6 weeks) or too late (continuing ineffective treatment), as cautioned by the American Academy of Child and Adolescent Psychiatry 1
• Don't neglect monitoring for side effects, which are a common reason for medication non-compliance, as noted by the American Academy of Child and Adolescent Psychiatry 4
• Avoid abrupt discontinuation of antipsychotics after acute symptom resolution, as maintenance therapy prevents relapse, according to the American Academy of Child and Adolescent Psychiatry 1

Management of Acute Psychosis

Initial Assessment and Treatment

• The British Journal of Psychiatry recommends performing a thorough assessment to rule out secondary causes of psychosis before initiating psychiatric treatment, and considering neuroimaging in patients with new-onset psychosis 5, 6
• The American College of Radiology suggests evaluating for potential medical causes including central nervous system infections, traumatic brain injury 6
• The British Journal of Psychiatry advises evaluating for risk of self-harm or aggression to determine appropriate treatment setting, and assessing level of community support and family's ability to manage the crisis 5

Pharmacological Management

• The Lancet Psychiatry recommends beginning antipsychotic treatment for patients who have experienced psychotic symptoms for a week or more with associated distress or functional impairment, and using atypical antipsychotics as first-line treatment due to better tolerability 5, 7
• The British Journal of Psychiatry suggests recommended initial target doses, such as Risperidone 2 mg/day and Olanzapine 7.5-10.0 mg/day 5

Psychosocial Interventions and Follow-up Care

• The British Journal of Psychiatry recommends including families in the assessment process and treatment planning, providing emotional support and practical advice to families, and developing supportive crisis plans to facilitate recovery and treatment acceptance 5
• The British Journal of Psychiatry advises ensuring continuity of care with treating clinicians remaining constant for at least the first 18 months of treatment, and monitoring for relapses 5, 8

Initial Management Approach for Acute Psychosis

Assessment and Treatment Setting

• The British Journal of Psychiatry recommends performing a thorough assessment to rule out physical illnesses that can cause psychosis before initiating psychiatric treatment, and providing treatment in outpatient services or home settings when possible and safe 9
• Consider inpatient care when the degree of crisis is too great for the family to manage or when there are safety concerns, as suggested by the British Journal of Psychiatry 9, 10

Pharmacological Management

• The British Journal of Psychiatry recommends initial target doses of risperidone 2 mg/day or olanzapine 7.5-10.0 mg/day for antipsychotic treatment 9, 10

Monitoring and Follow-up

• Monitor closely for extrapyramidal side-effects, which should be avoided to encourage future medication adherence, as recommended by the British Journal of Psychiatry 9
• If positive symptoms persist after a trial of an atypical antipsychotic, review the reasons for treatment failure, according to the British Journal of Psychiatry 9

Family Involvement and Psychosocial Support

• Include families in the assessment process and treatment planning, and provide emotional support and practical advice to families, as suggested by the British Journal of Psychiatry 9
• Progressively inform and educate families and other members of the person's social network about the nature of the problem, treatments, and expected outcomes, as recommended by the British Journal of Psychiatry 9, 10
• Ensure continuity of care, with treating clinicians remaining constant for at least the first 18 months of treatment, according to the British Journal of Psychiatry 10

Common Pitfalls to Avoid

• Don't delay treatment until a crisis develops, such as self-harm, violence, or aggression, as recommended by the British Journal of Psychiatry 9

Guidelines for Acute Psychotic Crisis Management

Immediate Pharmacologic Management

Safety Assessment and Risk Stratification

Maximum Dosing in First‑Episode Psychosis

Transition to Oral Antipsychotic Therapy

Hospitalization Criteria and Setting

Monitoring, Adverse‑Effect Management, and Adherence

Family Involvement and Psychosocial Support

Distinguishing Psychosis from Delirium and Identifying Secondary Causes

Immediate Safety Priorities

• Differential diagnosis: The first clinical priority is to differentiate psychosis from delirium because missed delirium carries approximately double the mortality and mandates a distinct, urgent management approach. 14

Diagnostic Workup

• Rule‑out secondary etiologies: Before labeling a presentation as a primary psychiatric disorder, clinicians must systematically exclude secondary medical causes of psychosis. 14
• Potential medical contributors: A broad range of conditions can precipitate psychotic symptoms, including endocrine disorders, autoimmune diseases, neoplasms, neurologic disorders, infections, metabolic abnormalities, nutritional deficiencies, and drug‑related effects. Comprehensive evaluation for these factors is essential. 14